Orphinic Scientific focuses on high quality assets in orphan diseases and other diseases with significant unmet needs, in line with proven business model of similar companies. Partnership with a large regional CRO represents an advantage in asset sourcing and qualification. As a result we expect above the market returns for the investors.
Orphinic Scientific possesses a best-in-class expertise in preclinical and clinical research. We plan, prepare and execute. The fast patient recruitment process is our hallmark.
Orphinic Scientific team has a broad access to key global biotech hubs and big pharma. Therefore we have a competitive advantage in sourcing top quality assets.
Our model is similar to existing very successful endeavours with repeatable high returns. After successful sale of first pipeline project our platform should become self-financing.
Orphinic Scientific has a collaboration agreement with a large clinical CRO operating in Central and Eastern Europe, which facilitates access to diverse patient populations and rapid enrollment to clinical trials supporting our projects. The CRO also helps sourcing and qualification of assets.
The portfolio of assets has high odds of success and large potential market value that should ensure high returns for our investors.